Astatine-211 for Acute Myeloid Leukemia
Trial Summary
What is the purpose of this trial?
This phase I/II trial studies the side effects and best dose of 211\^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before donor stem cell transplant.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research Team
Brenda M. Sandmaier
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
This trial is for patients with high-risk leukemias or myelodysplastic syndromes who have relapsed after remission, are not responding to treatments, or have disease evolved from other blood disorders. They must have low levels of leukemia cells in the blood and normal kidney and liver function. It's not suitable for those in first remission without measurable residual disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 211^At-BC8-B10 IV, potentially 131^I-BC8-B10 IV, fludarabine phosphate IV, undergo TBI and PBSC transplant, and receive cyclosporine and mycophenolate mofetil
Follow-up
Participants are monitored for safety and effectiveness after treatment, including SPECT, bone marrow aspirate, and blood sample collection
Treatment Details
Interventions
- 211^At-BC8-B10
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Research Center
Lead Sponsor
Fred Hutchinson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator